Navigation Links
Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
Date:11/28/2008

WAYNE, Pa., Nov. 28 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that on November 21, 2008, it received a letter from Nasdaq stating that since it had not yet filed its 10-Q for the quarterly period ended September 30, 2008 as of the date of the letter, it was no longer in compliance with the rules for continued listing according to Marketplace Rule 4310(c)(14).

The Nasdaq letter advised that Encorium had 60 calendar days from the date of the letter to submit a plan to regain compliance. Encorium filed its Form 10-Q for the quarterly period ended September 30, 2008 on Wednesday, November 26, 2008 and has notified Nasdaq of its filing. As a result, the Company anticipates it will receive notice from Nasdaq that it is currently in compliance with Nasdaq Marketplace Rule 4310(c)(14).

About Encorium Group, Inc.

Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug and biologics development as well as clinical trial experience across a wide variety of therapeutic areas such as infectious diseases, cardiovascular, vaccines, oncology, diabetes endocrinology/metabolism, gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women's health an
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
2. Encorium Reports Third Quarter 2008 Financial Results
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... company focused on the development of autologous cell ... Phase 1/2 clinical trial of RCT-01, being tested ... has been enrolled and their tissue biopsy sent ... is comprised of non-bulbar dermal sheath (NBDS) cells ...
(Date:6/29/2015)... ... ... This cutting edge standard making is a madatory tool for use in ... is the world’s first cuvette-shaped, solid-state filter that lets metrologists and quality control personnel ... calibration standards, such as those made from didymium glass were only able to operate ...
(Date:6/29/2015)... , June 29, 2015  AACC, a ... better health through laboratory medicine, is pleased to ... Clinical Chemistry , has increased to 7.9 ... This increase places Clinical Chemistry in ... reflects the significant influence of the research it ...
(Date:6/29/2015)... 2015   Veracyte, Inc . (Nasdaq: VCYT ... molecular cytology, today announced that it has been named ... list for the second year in a row. The ... an annual survey of Bay Area-company employees. ... to which Veracyte values our employees and their individual ...
Breaking Biology Technology:RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 3AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 2Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 3
... 22 Accelerated Community Oncology,Research Network (ACORN) ... and clinical trial network, announced today,that it ... of Business Development.,Webb brings a successful record ... has an exceptional background of work in ...
... Symbol: MS, - US$10 million received based on ... pivotal multiple sclerosis trial - EDMONTON, Sept. 22 ... in the treatment of multiple sclerosis (MS), today,announced that ... its,partner, Eli Lilly and Company., The milestone payment ...
... the Effects of Oral Calcitonin, a,combination of Salmon ... CEDAR KNOLLS, N.J., Sept. 22 Emisphere,Technologies, ... Novartis Pharma AG,and Nordic Bioscience have completed recruitment ... and efficacy of an oral formulation of,salmon calcitonin ...
Cached Biology Technology:ACORN Contract Research Organization Appoints Tara Webb as Senior Director of CRO Business Development 2ACORN Contract Research Organization Appoints Tara Webb as Senior Director of CRO Business Development 3BioMS Medical announces receipt of milestone payment from Eli Lilly and Company 2Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment 2Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment 3
(Date:6/30/2015)... -- To bolster its efforts and commitment to fighting cyber ... addition of two new team members. ... David Raviv will act as head of strategic alliances. ... providing the most secure solutions for the enterprise market. ... Technologies, a provider of security and management products, which was ...
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) has ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Biomedical Sensors market is estimated at $0.65 billion by ... 2014-2020 The near future will bring Biomedical ... each individual. These sensors can be set to trigger ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... deadly 1918 Spanish influenza pandemic is why it struck ... such as St. Louis spared the fate of the ... health measures? What made the difference, according to two ... (NIH), was not only how but also how rapidly ...
... cell came from remain distinct even after the cell becomes ... in the February 1 issue of Cancer Research. , ... quest to understand the causes of childhood brain cancers, according ... O. Schnuck Family Professor of Neurology at Washington University School ...
... that the risk of HIV transmission may be highest ... a study published in the April 1 issue of ... infection accounted for nearly half of all transmission occurrences ... Canada. , Bluma Brenner, PhD, and Mark Wainberg, PhD, ...
Cached Biology News:Rapid response was crucial to containing the 1918 flu pandemic 2Rapid response was crucial to containing the 1918 flu pandemic 3Rapid response was crucial to containing the 1918 flu pandemic 4Genetic fingerprints identify brain tumors' origins 2Risk of HIV transmission highest early in infection 2
Competitors to lower non-specific signal...
... anti-rabbit IgG FITC is used as ... staining on tissues or culture cells ... in rabbits. It is highly recommended ... omitting the primary antibody, be included ...
Complete cell culture media with cytokines...
8 different frozen tissues are mounted on positively charged glass slides...
Biology Products: